Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
128.60
+0.06 (0.05%)
Feb 21, 2025, 4:00 PM EST - Market closed
Intra-Cellular Therapies Analyst Ratings
Total Analysts
13
Consensus Rating
Buy
Price Target
$103.92
Upside
-19.19%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 21, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $119 → $132 | Strong Buy → Hold | Downgrades | $119 → $132 | +2.64% | Jan 31, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $108 → $132 | Buy → Hold | Downgrades | $108 → $132 | +2.64% | Jan 22, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $107 → $132 | Buy → Hold | Downgrades | $107 → $132 | +2.64% | Jan 14, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades $100 | Strong Buy → Hold | Downgrades | $100 | -22.24% | Jan 13, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $81 → $89 | Buy | Maintains | $81 → $89 | -30.79% | Nov 4, 2024 |
| Needham | Needham | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | -22.24% | Oct 31, 2024 |
| Needham | Needham | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | -22.24% | Oct 30, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $92 → $95 | Buy | Maintains | $92 → $95 | -26.13% | Oct 11, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $106 → $108 | Buy | Maintains | $106 → $108 | -16.02% | Oct 4, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $130 | Buy | Reiterates | $130 | +1.09% | Sep 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $130 | Buy | Reiterates | $130 | +1.09% | Sep 16, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $68 → $92 | Hold → Buy | Upgrades | $68 → $92 | -28.46% | Sep 6, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $79 → $81 | Buy | Maintains | $79 → $81 | -37.01% | Aug 21, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $107 → $106 | Buy | Maintains | $107 → $106 | -17.57% | Aug 8, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $120 → $130 | Buy | Maintains | $120 → $130 | +1.09% | Aug 8, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.